[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100584440":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":33,"centralContacts":34,"locations":40,"responsibleParty":59,"collaborators":33,"id":63,"slug":33,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":33,"eligibilityCriteria":67,"healthyVolunteers":64,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":33,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":89,"overallStatus":94,"whyStopped":33,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Cairo University","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"Deep carious molars, indirect pulp capping using PRF then GI base then composite restoration","EXPERIMENTAL",[12],"Biological: PRF",{"label":14,"type":15,"description":14,"interventionNames":16},"Deep carious molars, indirect pulp capping using MTA then GI base then composite restoration","ACTIVE_COMPARATOR",[17],"Drug: MTA",[19,26],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","MTA","The indirect pulp capping will be applied using MTA using an MTA carrier, then glass ionomer will be applied, then composite restoration above",[14],[25],"mineral trioxide aggregate",{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"BIOLOGICAL","PRF","The indirect pulp capping will be applied using PRF on a membrane, then glass ionomer will be applied , then composite restoration above",[9],[32],"platelet rich fibrin",null,[35],{"name":36,"role":37,"phone":38,"phoneExt":33,"email":39},"salma mohamed monir, MSc Cairo university","CONTACT","+201223035036","salma.elaraby@dentistry.cu.edu.eg",[41],{"facility":5,"status":33,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Giza","القاهرة - Cairo Governorate","11585","Egypt",{"type":47,"coordinates":48},"Point",[49,50],31.20861,30.00944,{"lat":50,"lon":49},[53,57],{"name":54,"role":37,"phone":55,"phoneExt":33,"email":56},"Eman Ali Abouauf, Assistant Professor","+2001001785300","e.abouauf@dentistry.cu.edu.eg",{"name":58,"role":37,"phone":33,"phoneExt":33,"email":33},"salma mohammed monir, MSc Cairo university",{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"PRINCIPAL_INVESTIGATOR","Salma Mohamed Monir Mahmoud Ahmed","Assistant lecturer","100584440",false,"NCT06889363","Clinical and Radiographic Evaluation of Indirect Pulp Capping Using Platelet Rich Fibrin Versus Mineral Trioxide Aggregate in Deep Carious Molars: a Randomized Controlled Trial","Inclusion Criteria:\n\n* o Patients with asymptomatic deep carious molars.\n\n  * Patients with clinically and radiographically confirmed deep carious lesions that do not exhibit spontaneous pain.\n  * Permanent molars only.\n  * Teeth with intact or minimally restored occlusal surfaces (i.e., no extensive restorations or fractures).\n  * No history of previous endodontic treatment or direct pulp capping on the study tooth.\n  * No signs of periapical pathology based on radiographic evaluation.\n  * Patients willing to participate and follow up for 12 months.\n  * Patients who agree to return for scheduled follow-ups at 3, 6, and 12 months.\n\nExclusion Criteria:\n\n* o Patients with systemic conditions affecting bone or tissue healing (e.g., uncontrolled diabetes, osteoporosis, immunosuppressed conditions).\n\n  * Pregnant or lactating women (if applicable to your study).\n  * Teeth with pulp exposure or necrotic pulp.\n  * Presence of symptomatic irreversible pulpitis (e.g., spontaneous pain, lingering pain).\n  * Periapical pathology or internal\u002Fexternal resorption detected radiographically.\n  * Severely broken down or non-restorable teeth.\n  * Calcified root canals or excessive sclerosis that could affect pulp testing reliability.\n  * Any pre-existing root canal treatment on the selected tooth.\n  * Patients who have undergone recent fluoride treatment, pulpotomy, or other pulp therapies in the past 6 months.\n  * Patients using medications affecting bone and tissue regeneration (e.g., bisphosphonates, corticosteroids).\n  * Patients unwilling or unable to commit to the 12-month follow-up schedule.\n  * Patients with poor oral hygiene or high caries risk that could compromise treatment outcomes.","ALL","20 Years","40 Years",{"count":72,"type":73},50,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","The aim of this study is the clinical and radiographic evaluation of (Platelet-Rich Fibrin (PRF) versus Mineral Trioxide Aggregate (MTA) in indirect pulp capping when used with deep carious molars over 1 year follow up.",[79,80,81,82,83,84,85,86,87,88],"Dental Caries","Pulp Caping","Indirect Pulp Treatment","Indirect Pulp Cap","Indirect Pulp Capping","Indirect Pulp Therapy","Deep Carious Lesion","Deep Carious Lesions","Molar Caries","Carious Molars",[90,21,28,91,92,93,32],"Molar caries","Indirect pulp capping","Deep carious lesion","carious molars","NOT_YET_RECRUITING","2025-03-17",{"date":97,"type":98},"2025-03-21","ACTUAL",{"date":100,"type":73},"2025-06",{"date":102,"type":73},"2026-09",{"name":5,"class":6},1]